Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: Implications for the 8-aminoquinoline class of anti-malarial compounds

Malaria Journal

Volumn 13, Issue 1, 2014, Pages

  Marcsisin, Sean R ^a   Sousa, Jason C ^a   Reichard, Gregory A ^a   Caridha, Diana ^a   Zeng, Qiang ^a   Roncal, Norma ^a   McNulty, Ronan ^a   Careagabarja, Julio ^a   Sciotti, Richard J ^a   Bennett, Jason W ^a   Zottig, Victor E ^a   Deye, Gregory ^a   Li, Qigui ^a   Read, Lisa ^a   Hickman, Mark ^a   Nanayakkara, N P Dhammika ^b   Walker, Larry A ^b   Smith, Bryan ^c   Melendez, Victor ^a   Pybus, Brandon S ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c US Army Medical Materiel Development Activity   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 AMINOQUINOLINE DERIVATIVE; ANTIMALARIAL AGENT; CYTOCHROME P450 2D6; LUCIFERASE; MICROBIAL ENZYME; NPC 1161B; TAFENOQUINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME METABOLISM; FEMALE; IMAGING SYSTEM; LUMINESCENCE; MALARIA CONTROL; MALE; METABOLIC ACTIVATION; MOUSE; NONHUMAN; PLASMODIUM BERGHEI;

AMINOQUINOLINES; ANIMALS; ANTIMALARIALS; CYTOCHROME P-450 CYP2D6; DOSE-RESPONSE RELATIONSHIP, DRUG; MALARIA; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PLASMODIUM BERGHEI; SUCCINATES;

EID: 84892729101     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-13-2     Document Type: Article

References (33)

1. Primaquine therapy for malaria. Baird JK, Hoffman SL, Clin Infect Dis 2004 39 1336 1345 10.1086/424663 15494911
2. Gametocytocidal and sporontocidal effects of primaquine upon two strains of Plasmodium falciparum. Rieckmann KH, McNamara JV, Kass L, Powell RD, Mil Med 1969 134 802 819 4987059
3. Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta). Dow GS, Gettayacamin M, Hansukjariya P, Imerbsin R, Komcharoen S, Sattabongkot J, Kyle D, Milhous W, Cozens S, Kenworthy D, Miller A, Veazey J, Ohrt C, Malar J 2011 10 212 10.1186/1475-2875-10-212 21801400
4. Optimising strategies for Plasmodium falciparum malaria elimination in Cambodia: primaquine, mass drug administration and artemisinin resistance. Maude RJ, Socheat D, Nguon C, Saroth P, Dara P, Li G, Song J, Yeung S, Dondorp AM, Day NP, White NJ, White LJ, PLoS One 2012 7 37166 10.1371/journal.pone.0037166 22662135
5. An LC-MS based study of the metabolic profile of primaquine, an 8-aminoquinoline antiparasitic drug, with an in vitro primary human hepatocyte culture model. Jin X, Pybus BS, Marcsisin SR, Logan T, Luong TL, Sousa J, Matlock N, Collazo V, Asher C, Carroll D, Olmeda R, Walker LA, Kozar MP, Melendez V, Eur J Drug Metab Pharmacokinet 2013 [Epub ahead of print] doi: 10.1007/s13318-013-0139-8
6. The metabolism of primaquine to its active metabolite is dependent on CYP 2D6. Pybus BS, Marcsisin SR, Jin X, Deye G, Sousa JC, Li Q, Caridha D, Zeng Q, Reichard GA, Ockenhouse C, Bennett J, Walker LA, Ohrt C, Melendez V, Malar J 2013 12 212 10.1186/1475-2875-12-212 23782898
7. CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine. Pybus BS, Sousa JC, Jin X, Ferguson JA, Christian RE, Barnhart R, Vuong C, Sciotti RJ, Reichard GA, Kozar MP, Walker LA, Ohrt C, Melendez V, Malar J 2012 11 259 10.1186/1475-2875-11-259 22856549
8. Metabolism of primaquine by liver homogenate fractions. Evidence for monoamine oxidase and cytochrome P450 involvement in the oxidative deamination of primaquine to carboxyprimaquine. Constantino L, Paixao P, Moreira R, Portela MJ, Do Rosario VE, Iley J, Exp Toxicol Pathol 1999 51 299 303 10.1016/S0940-2993(99)80010-4 10445386
9. Cytochrome P(450)-dependent toxic effects of primaquine on human erythrocytes. Ganesan S, Tekwani BL, Sahu R, Tripathi LM, Walker LA, Toxicol Appl Pharmacol 2009 241 14 22 10.1016/j.taap.2009.07.012 19616568
10. Hydroxylated metabolites of the antimalarial drug primaquine. Oxidation and redox cycling. Vasquez-Vivar J, Augusto O, J Biol Chem 1992 267 6848 6854 1313024
11. Direct ESR detection of a free radical intermediate during the peroxidase-catalyzed oxidation of the antimalarial drug primaquine. Augusto O, Schreiber J, Mason RP, Biochem Pharmacol 1988 37 2791 2797 10.1016/0006-2952(88) 90042-1 2840077
12. Hydroxyl radical formation as a result of the interaction between primaquine and reduced pyridine nucleotides. Catalysis by hemoglobin and microsomes. Augusto O, Weingrill CL, Schreier S, Amemiya H, Arch Biochem Biophys 1986 244 147 155 10.1016/0003-9861(86)90103-7 3004336
13. Peroxidation of the antimalarial drug primaquine: characterization of a benzidine-like metabolite with methaemoglobin-forming activity. Morais Mda S, Augusto O, Xenobiotica 1993 23 133 139 10.3109/00498259309059369 8498077
14. Oxidative activity of primaquine metabolites on rat erythrocytes in vitro and in vivo. Vasquez-Vivar J, Augusto O, Biochem Pharmacol 1994 47 309 316 10.1016/0006-2952(94)90022-1 8304975
15. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC, McCarthy WF, Deye G, Melendez V, Ockenhouse CF, N Engl J Med 2013 369 1381 1382 10.1056/NEJMc1301936 24088113
16. Cytochromes P450 and metabolism of xenobiotics. Anzenbacher P, Anzenbacherova E, Cell Mol Life Sci 2001 58 737 747 10.1007/PL00000897 11437235
17. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Zhou SF, Clin Pharmacokinet 2009 48 689 723 10.2165/11318030-000000000- 00000 19817501
18. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Bernard S, Neville KA, Nguyen AT, Flockhart DA, Oncologist 2006 11 126 135 10.1634/theoncologist.11-2-126 16476833
19. Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles. Bogni A, Monshouwer M, Moscone A, Hidestrand M, Ingelman-Sundberg M, Hartung T, Coecke S, Toxicol In Vitro 2005 19 621 629 10.1016/j.tiv.2005.04.001 15893449
20. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Ingelman-Sundberg M, Pharmacogenomics J 2005 5 6 13 10.1038/sj.tpj.6500285 15492763
21. Modeling human cytochrome P450 2D6 metabolism and drug-drug interaction by a novel panel of knockout and humanized mouse lines. Scheer N, Kapelyukh Y, McEwan J, Beuger V, Stanley LA, Rode A, Wolf CR, Mol Pharmacol 2012 81 63 72 10.1124/mol.111.075192 21989258
22. Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse. Walsh DS, Wilairatana P, Tang DB, Heppner DG Jr, Brewer TG, Krudsood S, Silachamroon U, Phumratanaprapin W, Siriyanonda D, Looareesuwan S, Clin Infect Dis 2004 39 1095 1103 10.1086/424508 15486831
23. Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand. Walsh DS, Looareesuwan S, Wilairatana P, Heppner DG Jr, Tang DB, Brewer TG, Chokejindachai W, Viriyavejakul P, Kyle DE, Milhous WK, Schuster BG, Horton J, Braitman DJ, Brueckner RP, J Infect Dis 1999 180 1282 1287 10.1086/315034 10479159
24. Efficacy of monthly tafenoquine for prophylaxis of Plasmodium vivax and multidrug-resistant P. falciparum malaria. Walsh DS, Eamsila C, Sasiprapha T, Sangkharomya S, Khaewsathien P, Supakalin P, Tang DB, Jarasrumgsichol P, Cherdchu C, Edstein MD, Rieckmann KH, Brewer TG, J Infect Dis 2004 190 1456 1463 10.1086/424468 15378438
25. A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum. Hale BR, Owusu-Agyei S, Fryauff DJ, Koram KA, Adjuik M, Oduro AR, Prescott WR, Baird JK, Nkrumah F, Ritchie TL, Franke ED, Binka FN, Horton J, Hoffman SL, Clin Infect Dis 2003 36 541 549 10.1086/367542 12594633
26. The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific. Elmes NJ, Nasveld PE, Kitchener SJ, Kocisko DA, Edstein MD, Trans R Soc Trop Med Hyg 2008 102 1095 1101 10.1016/j.trstmh.2008.04.024 18541280
27. Human CYP2D6 and mouse CYP2Ds: organ distribution in a humanized mouse model. Miksys SL, Cheung C, Gonzalez FJ, Tyndale RF, Drug Metab Dispos 2005 33 1495 1502 10.1124/dmd.105.005488 16033950
28. Use of CYP2D6 genotyping in practice: tamoxifen dose adjustment. Walko CM, McLeod H, Pharmacogenomics 2012 13 691 697 10.2217/pgs.12.27 22515611
29. In vitro activity of tafenoquine against the asexual blood stages of Plasmodium falciparum isolates from Gabon, Senegal, and Djibouti. Pradines B, Mamfoumbi MM, Tall A, Sokhna C, Koeck JL, Fusai T, Mosnier J, Czarnecki E, Spiegel A, Trape JF, Kombila M, Rogier C, Antimicrob Agents Chemother 2006 50 3225 3226 10.1128/AAC.00777-06 16940138
30. The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites. Delves M, Plouffe D, Scheurer C, Meister S, Wittlin S, Winzeler EA, Sinden RE, Leroy D, PLoS Med 2012 9 1001169 10.1371/journal.pmed.1001169 22363211
31. Genetic analysis of primaquine tolerance in a patient with relapsing vivax malaria. Bright AT, Alenazi T, Shokoples S, Tarning J, Paganotti GM, White NJ, Houston S, Winzeler EA, Yanow SK, Emerg Infect Dis 2013 19 802 805 10.3201/eid1905.121852 23648098
32. Recurrent Plasmodium vivax malaria due to dose-dependent primaquine resistance: a case report. Langholz Kristensen K, Dragsted UB, Scand J Infect Dis 2013 46 63 65 23957539
33. Primaquine in vivax malaria: an update and review on management issues. Fernando D, Rodrigo C, Rajapakse S, Malar J 2011 10 351 10.1186/1475-2875-10-351 22152065